- Fourth indication for injection treatment that can stabilize and improve vision
- mCNV a leading cause of visual impairment among those 20–50 years of age
Since its launch in Canada in 2007, Lucentis® has treated more than 100,000 eyes across all approved indications
DORVAL, QC, Oct. 8, 2014 /CNW/ – Novartis Pharmaceuticals Canada Inc. announced today that Lucentis®(ranibizumab), the treatment for several major causes of vision loss, has been approved by Health Canada for the treatment of visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV).
Myopic CNV (mCNV) develops in 5–10% of patients with pathologic myopia, which is a leading cause of blindness in many developed countries and second only to wet age-related macular degeneration in causing CNV. Abnormal blood vessels form beneath the retina of the eye and can rupture, leaking blood and fluid into the retina, causing vision loss. It is estimated that every day, almost five Canadians start experiencing vision loss from mCNV. In patients with untreated mCNV the long-term prognosis is poor, with approximately 90 per cent developing severe vision loss after five years. The condition is more than twice as prevalent in Asian populations as European populations.
“The thought of losing your vision can be devastating and the patients I see with this condition are generally young, healthy adults who are working and have a bright future before them. The approval of Lucentis® for mCNV equips us as physicians because until now we were only able to slow down vision loss in these patients,” said Dr. David Wong, Ophthalmologist-in-Chief at St. Michael’s Hospital in Toronto. “Improving vision in these patients allows them to continue working and get on with their busy lives.”
Lucentis® is an inhibitor of vascular endothelial growth factor (VEGF),…Read More: http://www.newswire.ca/en/story/1424878/-pr-lucentis-ranibizumab-approved-by-health-canada-to-treat-vision-loss-resulting-from-choroidal-neovascularization-in-pathologic-myopia-mcnv-1